arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CervoMed Inc.

CRVO
$2.87 ▲ +0.12 (+4.18%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

CervoMed Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $26.6M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -60.4%
FCF / Share $-0.87
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-7.96M
↓ -62.7%
Operating Margin Operating profit as % of sales
-376.4%
↓ -36.1%
FCF / Share Free cash flow per share
$-0.87
↓ -93.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 57 quarters